

# HTANGEL

Keeping you up-to-date on  
HTA decisions

## Issue 36: April 2026

### April HTA decisions bring strong oncology wins, but Alzheimer's and several targeted therapies face setbacks.

This newsletter summarises final decisions from NICE, SMC, HAS & IQWiG from published reports in April 2026.

#### Good news

**Pembrolizumab** approved in Scotland for locally advanced cervical cancer and in England for perioperative treatment of resectable locally advanced head and neck cancer; **Vorasidenib**, approved with special conditions in England for IDH1/2-mutated astrocytoma or oligodendroglioma after surgery; and **Belantamab mafodotin**, approved with special conditions in England for previously treated multiple myeloma.

#### Mixed news

**Toripalimab** was approved in Germany for recurrent nasopharyngeal carcinoma but not approved for metastatic nasopharyngeal carcinoma or oesophageal cancer.

#### Bad news

**Donanemab** had multiple non-approvals in Germany for early Alzheimer's disease; **Baloxavir marboxil**, not approved in Scotland for either treatment or post-exposure prophylaxis of influenza; and **Remimazolam**, not approved in Germany for either general anaesthesia or procedural sedation.

#### Approvals

15

#### Non-approvals

16

# HTANGEL


Issue 36: April 2026

## Pharmacological Technologies



England  
NICE TA1147

Cancer  
Astrocytoma,  
Oligodendroglioma  
VORASIDENIB



England  
NICE TA1146

Cancer  
Gastrointestinal  
stromal cancer  
RIPRETINIB



Scotland  
SMC2829

Cancer  
Cervical cancer  
PEMBROLIZUMAB



England  
NICE TA1145

Cancer  
Head and neck  
cancer  
PEMBROLIZUMAB



Scotland  
SMC2893

Cancer  
Chronic lymphocytic  
leukaemia  
ACALABRUTINIB



Scotland  
SMC2815

Cancer  
Lung cancer  
OSIMERTINIB



Scotland  
SMC2828

Cancer  
Endometrial cancer  
DOSTARLIMAB



France  
HAS AP573

Cancer  
Lung cancer  
LURBINECTEDINE



# HTANGEL

Issue 36: April 2026

## Pharmacological Technologies



Germany  
IQWiG A25-159

Cancer  
Lung cancer  
SELPERCATINIB



England  
NICE TA1149

Cancer  
Multiple myeloma  
BELANTAMAB  
MAFODOTIN



Germany  
IQWiG A26-04

Cancer  
Nasopharyngeal  
cancer  
TORIPALIMAB



Germany  
IQWiG A26-04

Cancer  
Nasopharyngeal  
cancer  
TORIPALIMAB



Germany  
IQWiG A26-05

Cancer  
Oesophageal cancer  
TORIPALIMAB




France  
HAS AP290

Cardiovascular  
Hereditary  
angioedema  
LANADELUMAB



Scotland  
SMC2923

Cardiovascular  
Pulmonary arterial  
hypertension  
SOTATERCEPT



France  
HAS AP577

Endocrine  
Type 1 diabetes  
mellitus  
TEPLIZUMAB



# HTANGEL

Issue 36: April 2026

## Pharmacological Technologies



France  
HAS AP575

Genetic & Metabolic  
Familial  
hypercholesterolaemia  
EVINACUMAB



Germany  
IQWiG A25-134

Neurology  
Alzheimer's disease  
DONANEMAB



France  
HAS AP578

Genetic & Metabolic  
Phenylketonuria,  
Hyperphenylalaninemia  
SEPIATERIN



Germany  
IQWiG A25-134

Neurology  
Alzheimer's disease  
DONANEMAB



Scotland  
SMC2920

Infection  
Influenza  
BALOXAVIR  
MARBOXIL



Germany  
IQWiG A26-29

Neurology  
Alzheimer's disease  
DONANEMAB



Scotland  
SMC2921

Infection  
Influenza  
BALOXAVIR  
MARBOXIL



Scotland  
SMC2922

Neurology  
Insomnia  
ESZOPICLONE



# HTANGEL

Issue 36: April 2026

## Pharmacological Technologies



Germany  
IQWiG A25-160

Neurology  
Myasthenia gravis  
NIPOCALIMAB



England  
NICE TA1148

Renal  
Hyperkalaemia  
SODIUM ZIRCONIUM  
CYCLOSILICATE




Scotland  
SMC2833

Skin  
Atopic dermatitis  
NEMOLIZUMAB



England  
NICE TA1144

Skin  
Generalised pustular  
psoriasis  
SPESOLIMAB



Germany  
IQWiG A25-163

Skin  
Psoriasis  
GUSELKUMAB



Germany  
IQWiG A25-162

Surgery  
General anaesthesia  
REMIMAZOLAM



Germany  
IQWiG A25-161

Surgery  
Sedation  
REMIMAZOLAM




# HTANGEL

Issue 36: April 2026

## Further Information

HTAngel is designed to help keep you up to date with the latest HTA decisions from NICE, SMC, HAS & IQWiG.

Below is a breakdown of the tiles in the newsletter.



At Crystallise we aim to provide an innovative approach to processing information, using software tools to automate processes that are slower and less accurate when done by humans. Our approach provides clients with greater transparency and scope than they could find for the same budget elsewhere. We work with a network of experts and organisations that help us support clients efficiently and effectively, and are proud of our flexible and ingenious way of solving their problems.

For further information about HTAngel contact  
[newsletter@crystallise.com](mailto:newsletter@crystallise.com)

To speak to us about our services contact  
[contact@crystallise.com](mailto:contact@crystallise.com)